Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer’s disease
AffiliationUniv Arizona, Sch Med, Ctr Innovat Brain Sci, Dept Pharmacol & Neurol
MetadataShow full item record
PublisherBIOMED CENTRAL LTD
CitationEvidence for benefit of statins to modify cognitive decline and risk in Alzheimer’s disease 2017, 9 (1) Alzheimer's Research & Therapy
JournalAlzheimer's Research & Therapy
RightsThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at email@example.com.
AbstractBackground: Despite substantial research and development investment in Alzheimer's disease (AD), effective therapeutics remain elusive. Significant emerging evidence has linked cholesterol, beta-amyloid and AD, and several studies have shown a reduced risk for AD and dementia in populations treated with statins. However, while some clinical trials evaluating statins in general AD populations have been conducted, these resulted in no significant therapeutic benefit. By focusing on subgroups of the AD population, it may be possible to detect endotypes responsive to statin therapy. Methods: Here we investigate the possible protective and therapeutic effect of statins in AD through the analysis of datasets of integrated clinical trials, and prospective observational studies. Results: Re-analysis of AD patient-level data from failed clinical trials suggested by trend that use of simvastatin may slow the progression of cognitive decline, and to a greater extent in ApoE4 homozygotes. Evaluation of continual long-term use of various statins, in participants from multiple studies at baseline, revealed better cognitive performance in statin users. These findings were supported in an additional, observational cohort where the incidence of AD was significantly lower in statin users, and ApoE4/ApoE4-genotyped AD patients treated with statins showed better cognitive function over the course of 10-year follow-up. Conclusions: These results indicate that the use of statins may benefit all AD patients with potentially greater therapeutic efficacy in those homozygous for ApoE4.
NoteOpen Access Journal.
VersionFinal published version
SponsorsNational Institute on Aging "Systems Pharmacology for Predictive Alzheimer's Therapeutics: SysPharmRx-AD" [R34 AG049652]; University of Southern California; James H. Zumberge Faculty Research and Innovation Fund at the University of Southern California; NIA [P30AG10161, R01AG15819I9, R01AG17917]
- A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease.
- Authors: Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, van Dyck CH, Aisen PS
- Issue date: 2011 Aug 9
- Statins, risk of dementia, and cognitive function: secondary analysis of the ginkgo evaluation of memory study.
- Authors: Bettermann K, Arnold AM, Williamson J, Rapp S, Sink K, Toole JF, Carlson MC, Yasar S, Dekosky S, Burke GL
- Issue date: 2012 Aug
- Effects of statins on cognitive function in patients with Alzheimer's disease in galantamine clinical trials.
- Authors: Winblad B, Jelic V, Kershaw P, Amatniek J
- Issue date: 2007
- Can statin therapy really reduce the risk of Alzheimer's disease and slow its progression?
- Authors: Miida T, Takahashi A, Tanabe N, Ikeuchi T
- Issue date: 2005 Dec
- KIF6 719Arg allele is associated with statin effects on cholesterol levels in amnestic mild cognitive impairment and Alzheimer's disease patients.
- Authors: Sabbagh M, Malek-Ahmadi M, Levenson I, Sparks DL
- Issue date: 2013